Application of a Quality by Design Approach to Develop a Simple, Fast, and Sensitive UPLC-MS/MS Method for Quantification of Safinamide, an Antiparkinson’s Drug, in Plasma

Safinamide is an orally active, selective monoamine oxidase-B inhibitor with dopaminergic and non-dopaminergic properties approved by the European Medicine Agency and US Food and Drug Administration for the treatment of mid- to late-stage fluctuating Parkinson’s disease (PD) used in combination with...

Full description

Bibliographic Details

Published in:	Separations
Main Authors:	Essam A. Ali, Mohamed A. Ibrahim, Muzaffar Iqbal, Rashad Alsalahi, Gamal A. Mostafa, Suliman Al Jarboua
Format:	Article
Language:	English
Published:	MDPI AG 2023-08-01
Subjects:	safinamide quality by design approach UPLC-MS/MS Parkinson’s disease metabolic stability
Online Access:	https://www.mdpi.com/2297-8739/10/9/474